Author

K. A. Luddy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. R. A. Anderson· 2 shared J. West· 2 shared M. Robertson-Tessi· 2 shared A. R. Anderson· 1 shared B. Desai· 1 shared C. Adam· 1 shared C. O'Farrelly· 1 shared F. Rentzeperis· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. R. A. Anderson

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Evolutionary double-bind treatment using radiotherapy and NK cell-based immunotherapy in prostate cancer

K. A. Luddy, J. West, M. Robertson-Tessi, B. Desai, T. M. Burrsell, S. Barrett, J. O'Sullivan, L. Marignol, R. Gatenby, J. S. Brown, A. R. Anderson, C. O'Farrelly

This study combines radiotherapy and NK cell immunotherapy to exploit an evolutionary double-bind strategy in prostate cancer, showing that RT-resistant cells become more vulnerable to NK cell killing.

bioRxiv · Mar 11, 2024 · PreprintCancer Biology

Tumor-immune metaphenotypes orchestrate an evolutionary bottleneck that promotes metabolic transformation

J. West, F. Rentzeperis, C. Adam, R. Bravo, K. A. Luddy, M. Robertson-Tessi, A. R. A. Anderson

This paper presents a multiscale mathematical model of tumor-immune interactions that identifies metaphenotypes driving immune escape and metabolic transformation in cancer.

bioRxiv · Jun 3, 2022 · PreprintCancer Biology

Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies

J. A. Gallaher, P. M. Enriquez-Navas, K. A. Luddy, R. A. Gatenby, A. R. A. Anderson

This study models how spatial heterogeneity and evolutionary dynamics affect cancer recurrence under different treatment schedules.

bioRxiv · Sep 8, 2017Cancer Biology